Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature

Marta Skoczynska, Mark A. Crowther, Malgorzata Chowaniec, Monika Ponikowska, Shruti Chaturvedi, Kimberly Legault

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: The purpose of this study was to characterize the role of eculizumab, a monoclonal antibody against the terminal complement component C5, in patients with catastrophic antiphospholipid syndrome (CAPS). Methods: We present a case report of a patient with systemic lupus erythematosus (SLE) and CAPS treated with eculizumab, as well as results of a systematic review of the literature. Results: Including our patient, we identified 11 case reports of patients with CAPS treated with eculizumab. All of them had partial or total remission of symptoms. Conclusion: Data on eculizumab efficacy in CAPS are promising but are limited to single case reports. More studies are needed to develop evidence-based recommendations for eculizumab use in CAPS.

Original languageEnglish (US)
Pages (from-to)631-639
Number of pages9
JournalLupus
Volume29
Issue number6
DOIs
StatePublished - May 1 2020

Keywords

  • Catastrophic antiphospholipid syndrome
  • eculizumab

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature'. Together they form a unique fingerprint.

Cite this